SER Company Profile and Key Details

SER has shown mixed momentum, gaining 16.19% over the past week and -40.31% over the past quarter, though year-to-date performance is up 50.03%. Short-term trend indicators are bullishly aligned (SMA20 -16.18%, SMA50 -25.13%, SMA200 -59.25%). The stock’s 14-day RSI is 40.43 (neutral), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -77.15% below its high and over 17.98% above its low. Average 10-day trading volume of 65.11 thousand shares is below the 3-month average of 1.27 million, indicating normal recent market interest.

Serina Therapeutics, Inc. generated EPS of $nan over the past year. Five-year average earnings growth is 33.3%. Wall Street analysts project EPS growth of 2.49% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $11.00. The high target offers 747.46% upside. The low target suggests 521.47% downside. The mean target is $13.67. This offers 672.32% upside. Serina Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 13, 2025, missed forecasts by -5.64%. The prior quarter beat by 83.33%. Over the last six quarters, Apple has recorded several small beats. These include -164.29% in March 24, 2025.

Serina Therapeutics, Inc. (AMEX:SER) closed at $1.77 USD, losing -$0.03 (-1.67%) from the previous close of $1.80. The stock is currently mid-range between its 52-week high and low $1.53 and $7.92. With a market capitalization of about $19.09 million, Serina Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.25). Key stats such as the average daily volume over the past year has been around 1.40 million shares, volume is running light vs its 52-week average. Headquartered in Huntsville, AL, Serina Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven A. Ledger, the company employs approximately 12 people and listed since January 21, 2000. Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.

Serina Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.38. This means the shares are trading above this model’s fair value.

Serina Therapeutics, Inc. has 10.25 million shares outstanding. The public float is 3.08 million shares, elevated short interest at 0.89% of float. This equals 51.31 thousand shares. The short ratio is 1.48 days. Institutional investors hold 8.26% of the float. Insiders own 47.3%. Bailey Gregory holds 67.24 thousand shares, MINTZ STEVEN has 17.44 thousand shares and Moreadith Randall has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 108.33 thousand shares across 27 transactions.

Serina Therapeutics, Inc. trades at a P/E ratio of -0.97, slightly below the S&P 500 average, with a price-to-sales ratio of 162.25 and a price-to-book ratio of 10.25 reflecting a rich premium to book value. The P/FCF stands at -1.14, also above market averages. Compared to sector medians, Serina Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Serina Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.9%, with price expected at $1.40 by March 13, 2026, within a range of $0.97 to $1.86 3-Month Outlook: Projected fall of -49.15%, reaching $0.90 by May 28, 2026, with a range of $0.73 to $1.09. 1-Year Outlook: Projected loss of -45.2%, with price at $0.97 by February 26, 2027, within a range of $0.53 to $1.38.

Serina Therapeutics, Inc. (AMEX:SER) shares are up 50.03% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Serina Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.97. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.67, suggesting 672.32% upside. Our AI forecast model points to short-term weakness (-20.9% over two weeks), a medium-term fall (-49.15% over three months), and a longer-term loss (-45.2% over one year), with expected trading ranges indicating moderate volatility.